FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
The FDA approved BridgeBio Pharma's Attruby for ATTR-CM, showing reduced cardiovascular risks and improved quality of life. The drug stabilizes TTR, targeting the root cause of the disease. BridgeBio aims for European approval by 2025. Bayer has rights for commercialization in Europe.